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Abstract: There is a widespread awareness that the wealth of preclinical toxicity data that 
the pharmaceutical industry has generated in recent decades is not exploited as efficiently 
as it could be. Enhanced data availability for compound comparison (“read-across”), or for 
data mining to build predictive tools, should lead to a more efficient drug development 
process and contribute to the reduction of animal use (3Rs principle). In order to achieve 
these goals, a consortium approach, grouping numbers of relevant partners, is required. The 
eTOX (“electronic toxicity”) consortium represents such a project and is a public-private 
partnership within the framework of the European Innovative Medicines Initiative (IMI). 
The project aims at the development of in silico prediction systems for organ and in vivo 
toxicity. The backbone of the project will be a database consisting of preclinical toxicity 
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data for drug compounds or candidates extracted from previously unpublished, legacy 
reports from thirteen European and European operation-based pharmaceutical companies. 
The database will be enhanced by incorporation of publically available, high quality 
toxicology data. Seven academic institutes and five small-to-medium size enterprises 
(SMEs) contribute with their expertise in data gathering, database curation, data mining, 
chemoinformatics and predictive systems development. The outcome of the project will be 
a predictive system contributing to early potential hazard identification and risk assessment 
during the drug development process. The concept and strategy of the eTOX project is 
described here, together with current achievements and future deliverables. 
Keywords:  predictive toxicology; in silico toxicity; in vitro toxicity; in vivo toxicity; 
Knowledge Management; Expert Systems; Decision Support System; Data Integration; 
Manual Curation; ontology; histopathology; computational models; QSAR; data sharing 
 
1. Introduction: Shortcomings of Toxicology in Current Drug Development 
The main barrier for a new drug to enter into clinical development is the preclinical evaluation of 
toxicity, where the systemic rodent and non-rodent toxicity studies are the pivotal investigation 
paradigms (as described in various guidelines e.g. International Conference of Harmonisation Topic M 
3 (R2)) [1]. Approximately 35% of all drug development projects fail as a result of toxicity detected 
during preclinical safety studies [2], therefore animal studies are an important safeguard for the safety 
of patients. In order to front-load identification of toxic effects into earlier phases of development, 
where several candidates are under investigation and lead compounds can still be modified, in vitro 
screening assays have been developed for a variety of toxicological endpoints (for an overview see [3]). 
While predictive screening assays are useful for endpoints such as genotoxicity and hERG inhibition, 
the complex interplay of factors that lead to systemic or organ toxicity in vivo is not effectively 
represented in vitro. Assays for phospholipidosis [4], off-target pharmacology profiling and inhibition 
of the hERG channel [5] in vitro are useful to identify hazards and thus contribute to the design of 
more hypothesis-driven in vivo studies. However, while in vitro approaches can offer a certain 
mechanistic insight, they are rarely able to provide risk assessment information for the in vivo situation, 
i.e., a decision to terminate a compound or a chemical series is rarely based on the outcome of   
such assays. 
In terms of computational approaches, there are in silico models focusing on, for example, the 
prediction of genotoxicity, skin sensitization and hERG inhibition, that show a reasonable predictive 
accuracy [6–8]. Nevertheless, the available computational models to predict in vivo toxicity in general 
and organ toxicity in particular [9–12] typically cover only a narrow chemical space due to the small 
training sets available, and are of poor predictive value, thereby limiting their use in drug discovery 
projects. General issues with computational modeling of in vivo toxicity arise from the complexity of 
the endpoints, the need to implement a prediction of exposure for risk assessment and the lack of data 
sets with appropriate size, quality, and coverage of the large chemical space in which the prediction 
must be made (a prerequisite for building robust models). Indeed, most in silico models have been Int. J. Mol. Sci. 2012, 13  
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developed for the prediction of simpler endpoints represented by binding to a single biomolecule, and 
their extension to in vivo endpoints will probably require the prediction of a variety of involved 
mechanisms or pathways and their subsequent integration using methods that simulate theunderlying 
physiology. 
As a result of the lack of reliable in silico and in vitro models for the prediction of in vivo toxicity, 
most pharmaceutical companies have introduced an early in vivo ‘minitox’ assay with repeated dosing 
over one or two weeks in rodents and/or non-rodents, in order to predict the outcome of the larger, 
more expensive GLP (Good Laboratory Practice) studies. The pervasiveness of this practice clearly 
demonstrates that there is still a need for better and earlier toxicity prediction. Improved in silico 
models could help to optimize the design of such systemic toxicity studies, or even replace some of 
them, thus contributing to the replacement, refinement and reduction of animal use in research and 
testing, known as the principle of the 3Rs [13]. 
Since the definitive introduction of the good laboratory practice (GLP) principles in 1981, all 
preclinical toxicity studies generated by the pharmaceutical industry strictly follow GLP rules, 
ensuring high data quality in the study reports. Whereas every company archives all generated data in 
a fully traceable manner, this information is not stored in a way that allows retrieval of study 
conclusion data in a structured format for the generation of simple statistics across the reports of a 
given company, let alone the entire industry. Indeed, it would be of great interest to the industry to be 
able to analyze this data and learn how to avoid costly failures in the future. The data in the collected 
preclinical toxicity reports of pharmaceutical companies represents the most important data source for 
improved in silico toxicity model building. Perhaps surprisingly, none of the 13 companies involved in 
eTOX project currently has the ability to answer simple questions from their own data such as: “What 
type of compound-induced liver toxicity is the most commonly observed in rat across all studies?” or 
“What is the translatability of toxicity findings across species?”. Such questions could be answered by 
extracting the data from study reports and putting this information into a structured database. This is 
especially true if all companies could share this data. Of course, many more complex and meaningful 
questions could be generated to exploit this toxicological “gold mine” and more may be learnt from the 
past to improve future medicines. Currently, very few pharmaceutical companies have unilaterally 
decided to reorganize their preclinical toxicity archives and extract the data to build searchable and 
mineable databases given the considerable investment in terms of time and money that is required. 
Hence, one of the main goals of eTOX was to also organize the extracted data into a searchable 
structure with appropriate tools.  
Since eTOX is still in the phase dominated by data extraction, collection and database construction, 
the achievements with regard to modeling and predictive tools are still limited. Therefore, the main 
objective of this article is to provide an overview on the concept and strategy of the eTOX project to a 
broader audience. In addition, the design of the database and the strategy to overcome the problems of 
data sharing in the context of intellectual property will be explained. Although the early predictive 
models will be reported, subsequent publications will focus on details of the modeling approaches and 
performance of the predictive tools developed in the frame of eTOX. 
 Int. J. Mol. Sci. 2012, 13  
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2. The Innovative Medicines Initiative as Framework For Improving Toxicity Assessment in 
Drug Development 
In 2008, a group of preclinical safety scientists from the pharmaceutical industry recognized that, 
collectively, they were sitting on the largest collection of unpublished, high quality in vivo toxicity 
data in existence. More importantly, they realized the potential benefit of a collaborative approach to 
the sharing of corporate toxicology data that could provide a significant advance in predictive 
toxicology by overcoming some of the shortcomings described above. Toxicity data acquired during 
drug development is not routinely published or shared in public databases owing to the confidential 
nature of the research that generates the data. However, sharing these data would not only allow the 
comparison of new structures to already existing data and thus contribute to the principle of the 3Rs by 
a more refined design of in vivo studies, but would also constitute the basis for the development of 
more reliable computer models to assist in the prediction of in vivo toxicity.   
As a consequence, the European Innovative Medicines Initiative (IMI), a public-private partnership 
of the European Union and the European Federation of Pharmaceutical Industries and Associations 
(EFPIA), launched a call for a project to be funded to achieve this goal of data sharing and building of 
new in silico safety models. IMI [14] plays an important role in this endeavor, being Europe's largest 
public-private initiative aiming to speed up the development of better and safer medicines for patients. 
IMI supports collaborative research projects and builds networks of industrial, small and medium 
enterprises (SMEs) and academic experts in order to boost pharmaceutical innovation in Europe. 
Eleven expressions of interest from consortia of academic institutions and small-to-medium 
enterprises (SMEs) were submitted for the above-mentioned topic and subsequently evaluated by 
independent experts during 2008. The project selected was “Integrating bioinformatics and 
chemoinformatics approaches for the development of expert systems allowing the in silico prediction 
of toxicities” (eTOX, “electronic toxicity” [15]) submitted by the academic institutions and SMEs 
listed in Table 1. The main objectives of this project are: to identify and implement ways for data 
sharing while safeguarding intellectual property; to build a harmonized toxicological database; and to 
use this database for the development of predictive models. In total, thirteen EFPIA companies have 
decided to participate in the project consortium (see Table 1).  
Proprietary structural and pharmacological knowledge on chemical entities represent the main 
assets of each pharmaceutical company. It was therefore crucial to identify during the preparatory 
phase of the project, ways to share this knowledge without endangering a company’s competitive 
advantage. After overcoming this initial hurdle, the eTOX project officially started on 1 January 2010.  
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Table 1. Partners in the eTOX project.  
Private  Public 
EFPIA Companies  Academic Institutions  SMEs 
 
Novartis Pharma 
 
Fundació Institut Mar d’Investigacions 
Mèdiques, Barcelona, Spain  
Lhasa Limited, Leeds, UK 
 
AstraZeneca  Fundación Centro Nacional de 
Investigaciones Oncológicas Carlos III, 
Madrid, Spain 
Inte:Ligand GmbH, Vienna, Austria
 
Boehringer Ingelheim 
 
European Molecular Biology Laboratory 
(European Bioinformatics Institute), UK 
Molecular Networks GmbH, 
Erlangen, Germany 
 
Bayer HealthCare 
 
Liverpool John Moores University, 
Liverpool, UK 
Chemotargets SL, Barcelona, Spain
 
Laboratorios del DrEsteve 
 
Technical University of Denmark, 
Kopenhagen, Denmark 
Lead Molecular Design SL, Sant 
Cugat del Vallès, Spain 
GlaxoSmithKline  Universität Wien, Vienna, Austria  
Janssen Pharmaceutical 
 
Vrije Universiteit Amsterdam, The 
Netherlands 
 
UCB Pharma     
H. Lundbeck     
Pfizer Ltd.     
F. Hoffmann-La Roche     
Sanofi *
     
Les Laboratoires Servier *     
(Organizations leading the project are depicted in bold, * Companies that joined eTOX after its 
inception. Note: Sanofi, formerly Sanofi-Aventis).  
3. Improving Toxicity Prediction—The eTOX Project 
The eTOX project is focused on the development of innovative strategies for the in silico prediction 
of the in vivo toxicities of drugs, and their implementation into integrated and customizable software 
tools. The intended predictive system, eTOXsys (see section 3.7), aims to significantly improve the 
quality of the current state-of-the-art computational predictions [16,17] for the pharmaco-toxicological 
profiles of new drug candidates. The eTOX project has some aspects in common with other European 
projects and initiatives such as, OpenTox (focused on environmental toxicity) [18] or the OSIRIS 
project [19]. However, eTOX is substantially different in terms of the concept, strategy and scientific 
and technological approaches applied as described below (see Figure 1 for an overview of the eTOX 
project strategy):  Int. J. Mol. Sci. 2012, 13  
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  Creation and maintenance of an integrated database of high-quality data of in vivo preclinical 
toxicology and in vitro pharmacology for drug-like molecules [20]. The selection and 
classification of the records to be shared among the EFPIA companies, the development and 
application of appropriate standards and ontologies (with a focus on histopathology 
descriptions), and setting up of strategies for data quality assessment, will be key tasks for the 
establishment of the intended, integrated database. This database will be hosted by one of the 
partners (Lhasa Limited), acting as “honest broker” of the data. 
  Development and implementation of strategies (procedural and technological) for protecting 
sensitive information coming from the participating pharmaceutical companies. Since part of 
the molecular structures will be particularly sensitive information to be protected, encoding by 
means of the irreversible transformation of structures into molecular descriptors is to be 
considered [21].  
  Development and application of text mining techniques required for the automatic exploitation 
of biomedical literature and legacy reports of the pharmaceutical industry. The intended text 
mining techniques will go beyond the classical co-occurrence analysis by incorporating natural 
language processing [22]. 
  Application of computational techniques for the prediction of pure chemistry-related 
toxicology (e.g. cationic amphiphilic drugs and phospholipidosis) by means of sub-structure or 
fragment-based approaches, as well as by the detection of toxicophores.  
  Implementation of strategies for the prediction of off-target pharmacology by means of the 
automatic analysis of similarities between the studied compounds and extensive collections of 
biologically annotated ligands stored in chemogenomic databases, as well as by performing 
docking simulations of the studied compounds in structural models of key off-target interaction 
such as the hERG K+ channels [23]. 
  In silico prediction of the interaction of drugs with a relevant panel of drug transporters [24] as 
well as metabolism predictions will be developed, since drug transport and metabolism play a 
key role in triggering or avoiding some of the toxic or side effects of drugs [25]. Aspects of 
metabolism will be covered using the Meteor software (Lhasa Limited, Leeds, UK), also see 
Marchant et al. [26], MetaSite (Molecular Discovery Ltd., Pinner, UK), also see Cruciani et al. 
[27] and CRAFT (Molecular Networks GmbH, Erlangen, Germany) programs. 
  Development of large-scale QSAR models for the prediction of toxicity outcomes. Molecular 
and physicochemical descriptors and multivariate analysis techniques, hierarchical and block-
oriented methods will be applied, as well as neural networks and Bayesian methods [28]. 
  Incorporation of -omics data and cross-omics mapping in order to understand and model 
toxicological phenomena observed in vivo [29]. The modeling of biological pathways in a way 
that allows for the assessment of the perturbations produced by drugs is one of the aims of this 
project. Comparative genomics analysis will also be implemented to address the variations in 
the toxicological features observed in different species.  
 
As each of the aforementioned approaches on their own will generate a prediction that forms part of 
a bigger picture, or prediction, for the chemical, a key activity of the project will be the development 
of integrative algorithms (including decision trees, reasoning and consensus models), together with Int. J. Mol. Sci. 2012, 13  
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expert systems reasoning (i.e., Derek Nexus [30]), in order to combine the series of particular 
predictions into a more powerful and comprehensive strategy and software framework for 
toxicological assessment. However, in contrast to projects that are open to the public, the eTOX 
project contains a large amount of proprietary data donated by the consortium members which requires 
a level of confidentiality with respect to chemical structures and targets (see Figure 2). This requires a 
specific effort to protect sensitive information that is not of concern to a web based open information 
system as that provided by OpenTox. The eTOXsys will use web services not exposed to the public. In 
the final version, the system will be installed behind corporate firewalls, protecting the confidentiality 
of compounds under investigation.   
An iterative process consisting of system development, experimental validation, critical assessment 
and system improvement will be devised. The experimental validation rounds will be carried out on 
series of compounds not used for the development of the applications. The characterization, evaluation 
and validation of QSARs will be performed following the OECD principles [31], taking advantage of 
the participation of one of the eTOX partners in the OECD Expert Group. 
Figure 1. Overview of the eTOX project strategy. eTOX collects toxicological data from 
pharmaceutical (EFPIA) companies and public sources, and incorporates them into a 
database hosted by the “honest broker” to safeguard IP issues related to these data. The 
database will then serve as a source for the development of in silico models to predict the 
in vivo toxicity of new drugs. 
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Figure 2. The sensitivity classifications used in the eTOX project 
 
3.1. Construction of the eTOX Database 
The eTOX consortium is currently building a large database containing proprietary compound and 
animal safety data from pharmaceutical companies, previously inaccessible to anyone but the 
respective owners. This will be integrated with publicly available data sources. As mentioned above, 
the database will be hosted by Lhasa Limited, which acts as “honest broker”. Lhasa Limited was 
selected on the basis of their previous experience in data sharing projects and the fact that Lhasa had 
already developed a searchable toxicological database that could be used and modified for the 
purposes of eTOX. Lhasa Limited is a not-for-profit, charitable organization that exists to promote the 
sharing of data and knowledge in chemistry and life sciences. This organization has extensive 
experience in the role of honest broker for the sharing of mutagenicity data on impurities stemming 
from the drug manufacturing process and the results of repeated dose studies on pharmaceutical 
excipients [26]. Lhasa Limited has previously developed the Vitic Nexus software, a chemically 
intelligent toxicity database, to facilitate such sharing. 
The schema of this database is self-describing and can easily be modified to meet the specific 
requirements of individuals or groups. Vitic Nexus incorporates editing tools to enable in-house data to 
be imported and edited, together with an SDFile import utility for uploading new data in batch mode. 
The software supports similarity as well as exact match and substructure searching. Sophisticated 
searches can be built up by defining multiple criteria and combining them using Boolean logic. In this 
way, chemical structure searches can be combined with text searches, including toxicological criteria 
and experimental protocol constraints. Multiple databases can be searched simultaneously and the 
results from all searched databases displayed together. 
The establishment of data-sharing strategies requires agreement on the format and extent of data to 
be contributed by each participating organization. The primary focus for data collection are the 
systemic toxicity studies (1–4 week repeated dose studies in rodent, dog and other non-rodent) but data 
collection is intended to be extended to longer studies, as well as to pharmacokinetic/toxicokinetic 
studies, in vivo safety pharmacology and gene expression data sets during the course of the project. Of Int. J. Mol. Sci. 2012, 13  
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the several thousand systemic toxicity studies already identified across all the participating EFPIA 
companies, most are rat studies. In addition, approximately 925 new repeat dose toxicity studies are 
performed in total each year within the participating EFPIA partners, of which about 550 are rat 
studies. It is hoped that the majority of these studies will also be made available to the project. 
The schema for the database has been developed in an iterative manner. The first draft, created by 
Bayer Healthcare, was implemented into Vitic Nexus by Lhasa Limited and several improvements 
were made during the course of a pilot study, based on the feedback received from participating 
contract research organizations (CROs) extracting the data together with the EFPIA partners. 
A further review of the schema is planned when the database is more fully populated. As a next step, 
schemas covering non-rodent species and further types of preclinical studies such as receptor and 
enzyme screening data will be implemented. Additional tables, if needed, will be defined, based on 
examples of the data to be captured. Subgroups will be set up consisting of consortium members with 
experience of the data being captured who will advise on: 
  Those values/fields users are likely to include in their queries; 
  Formats for displaying or reporting the results; 
  Those values/fields important for determining data quality; 
  Those values/fields important for developing predictive models. 
3.2. Safeguarding Intellectual Property 
The development and implementation of procedural and technological strategies for the protection 
of sensitive information is required in order to allow sharing of information among the participating 
pharmaceutical companies. A combination of legal contracts, physical access controls, software 
controls, sensitivity levels (Figure 2) and structure masking were elaborated to ensure the optimal 
protection of the sensitive, shared data. Obtaining permission to release data from EFPIA legacy 
reports to the consortium represents a crucial and potentially time-limiting step for the eTOX project. 
The procedures for getting such permissions vary between companies: compounds which have fallen 
into the public domain may be considered as the least critical and, whilst some companies regard data 
on marketed substances as most sensitive, for others it is data from development projects. Structures 
from terminated projects may gain importance, as they may be ‘re-discovered’ for different projects or 
indications. Most companies need to get permission for each structure and/or for each report 
individually from their R&D heads and their patents & licensing groups. Bayer Healthcare has 
elaborated a procedure to get a general permission for full or restricted sharing. Classification of 
structures or reports according to confidentiality levels is being run in parallel to data extraction in 
order to speed progress towards the final goal, the donation of data to the eTOX database. 
Data classified as “non-confidential shared data” will be accessible to all project participants. Data 
classified as “confidential shared data” will be held by the honest broker, but will be accessible only by 
the original owner of the data. Modelers who intend to mine these data will have to agree a secrecy 
agreement with the data owner. The honest broker will not only provide the physical barrier system but 
also manage the secrecy agreements and control subsequent data access. In addition, all partners have 
signed an agreement to not attempt to reverse engineer masked structural information that they will 
obtain during the project. Int. J. Mol. Sci. 2012, 13  
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3.3. Data Extraction and Gathering 
 
Extracting and gathering the data from legacy reports represents the rate-limiting step for all 
subsequent data mining and predictive model building. The process was initiated in parallel with the 
development of the database and will continue throughout the duration of the project. In line with the 
priorities set in the project proposal, data collection commenced with summary data from systemic 
toxicity studies in rodents. It is planned to incorporate raw data into the final database wherever 
possible in order to be able to mine for previously unknown relationships and on an individual animal 
basis, if needed. A survey of the EFPIA partner companies at the start of the project estimated the 
number of repeat dose toxicity reports (1 to 4 weeks administration) eligible for the project to be 
roughly 10,736, comprising around 1,900 different chemical structures. The current evaluation of the 
existing reports and the accompanying intellectual property situation suggests that approximately 20% 
of non-confidential data sets can be fully shared among the partners. 
In order to make the data available in a machine-readable format, a data extraction process is 
required. Manual data extraction inside the EFPIA companies was previously proven to be both time 
and cost-intensive and was identified as a potential, major bottleneck of the project. 
Several subcontractors offering manual or semi-automated data extraction were evaluated in a 
feasibility study using a small number of reports with diverse characteristics. The aim of this ‘data 
extraction pilot study’ was to identify contract research organizations (CROs) with sufficient capacity, 
good quality standards, assurance of confidentiality and competitive offers with respect to time and 
costs. Following the evaluation, the EFPIA partners agreed a shortlist of three CROs and it will be at 
the discretion of each EFPIA partner to decide whether they will enter the data themselves or employ 
one of the shortlisted CROs to do the data extraction for them. The data extraction process is briefly 
outlined in Figure 3. Currently, there are 2091 reports identified for sharing within the project, of 
which 1648 have been submitted to CRO’s for extraction. Of these, 106 of which have been already 
completed and 15 are in the Vitic database. It is expected that the majority of identified reports will be 
accessible to the modelers in the project by the end of this year. 
Figure 3. Summary of the data transfer process. 
 Int. J. Mol. Sci. 2012, 13  
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Efforts are underway to gather relevant data from public sources (e.g. scientific literature and   
non-proprietary databases, see Figure 4). Published datasets that are thought to be of good quality and 
appropriate for the project as training and validation datasets for predictive models have been 
identified and made available in a repository within the eTOX intranet. This repository, monthly 
updated and maintained by Fundació Institut Mar d’Investigacions Mèdiques (FIMIM), will be 
gradually included into the ChOX database. ChOX [32] is an internal repository based on the 
ChEMBL [33] database implementation, developed by European Molecular Biology Laboratory 
(EMBL). The first version contains 2D structural and physicochemical information on 153,520 distinct 
compounds annotated with bioactivity data on 384 proteins (particularly populated with CYP450, 
transporters and off-target data with relevance to toxicity assessment). The biological information that 
is currently incorporated corresponds to 415,051 bioactivity data points across seven species, extracted 
from 9,101 publications. 
The considered bioactivities are essentially binding data (IC50 and Ki) and pharmacological data 
(EC50). The pharmacokinetic (PK) data so far included in ChOX is for bioavailability, clearance, 
volume of distribution and half-life, and includes data from four species. There are several ways to 
browse and to analyze the data, including exact, substructure and similarity structural searches, 
specific physicochemical parameters (MW, AlogP, PSA), type of activity (IC50, Ki, EC50) and 
molecular target. 
Future plans include the addition of publicly available data from toxicogenomics experiments via 
array express or GEO (Gene Expression Omnibus) [34] with links provided from the ChOX interface. 
The user will also have the ability to query ChemProt and ChEMBL in parallel to ChOX. 
 
Figure 4. Gathering and harmonization of data from EFPIA partners and public sources: 
Strategy to populate the eTOXdb with data suitable for model building. 
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3.4. Development of Database Standards 
The pilot data extraction study highlighted the need for a consensus to be reached on how the 
database schema should be populated. Therefore, the questions and answers generated during the pilot 
study have been used to define data entry guidelines to ensure consistency among the various CROs 
and EFPIA partners entering data. For modeling purposes, it is important to enter both positive and 
negative findings and to include data for control groups. Any evidence of background findings such as, 
for example, cardiomyopathy will also be captured. 
The EFPIA partners and Lhasa Limited will carry out quality assessments and consistency checks 
on the extracted data. Owing to the heterogeneity of the study data, it has been necessary to identify 
ways to harmonize the measurement units used for quantitative data and to develop ontologies. 
3.5. Ontologies for Preclinical Safety 
Ontologies are formal representations of knowledge within a specific domain that show the 
relationships between different concepts in that domain. Ontologies and controlled vocabularies with 
synonym mapping are extremely important for a project like eTOX because they allow the terms that 
have evolved over time, across all the different companies, and those in public literature to be mapped 
to a single preferred term. As a result of their hierarchical structure, ontologies allow the grouping of 
findings from different studies at different levels of the tree, which can help solve the issue of different 
pathology descriptions of a finding with different levels of specification (e.g. “chronic inflammation” 
vs. “inflammation”). This is essential for cross study data analysis as well as the development of 
models. It is hoped that this work will also contribute to an industry standard ontology for   
preclinical findings.  
In previous efforts to create microscopic finding ontologies, a finding was always linked with an 
organ, i.e., “Liver necrosis” and treated as a single term. This means that the term “necrosis” must be 
entered many times into the ontology as it can occur in different tissues. In eTOX, it was decided to 
separate the finding from the anatomy so that the term necrosis stands alone and the term liver stands 
alone. Based on previous experience accumulated in Novartis, it was decided to follow a different 
approach for developing a preclinical safety ontology, taking into account the following requirements: 
The ontology must, 
  Be easy to maintain.  
  Allow a flexible mapping of findings for later computer modeling. For the example of liver 
necrosis when using a machine learning approach, the feature “finding” (e.g. necrosis) will be 
treated separately from the feature “anatomical region” or “organ” (e.g. liver) which will allow 
the machine learning algorithm to automatically analyze compounds causing necrosis across all 
tissues or all findings in liver.  
  Enable the creation of hard links (where needed) between the different ontologies (i.e. to link 
the pathology finding “hyperostosis” to the rather high level anatomy term “bone”). 
 
While the ontologies are important for later modeling, they are not required for initial data capture 
from study reports. Most of the EFPIA companies do not have access to the lists of terms used in their Int. J. Mol. Sci. 2012, 13  
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company until the verbatim terms are captured from the reports. Therefore, it was decided to extract 
verbatim, findings terminology from the reports and to map them into the ontologies afterwards. The 
listing of ontologies/vocabularies that need to be created and some key characteristics are   
described below: 
  The Anatomy Ontology: A list of terms and relationships that describe the anatomical locations, 
organs or tissues from any animal used in preclinical safety experiments. Starting with the 
Adult Mouse Anatomy Ontology created at the Jackson Laboratories [35], all the terms in use 
in the Novartis preclinical databases have been mapped to this ontology as synonyms and 
expanded with new terms where appropriate. This is a relatively complete ontology and it was 
found that of the 1,600 terms from all species existing in the Novartis database, almost 90% 
were mapped as synonyms and only about 150 had to be added as new preferred terms. While 
the anatomy ontology is based on a mouse ontology, it is useful for all species used in 
preclinical safety studies with only minor modifications, such as the creation of links to a 
particular species for some terms (i.e. linking “harderian gland” to “rodents” in the species 
ontology). 
  The Microscopic Pathology Ontology: This was the most difficult ontology to create, as it has 
to be built from ‘de novo’. An attempt was made to find an existing public ontology that met 
the needs of preclinical safety pathologists but none were available that matched the 
terminology currently used. Therefore, eTOX worked closely with pathologists at Novartis and  
GlaxoSmithKline to create the backbone of a new ontology. This ontology will be used to map 
all terms existing in the Novartis preclinical safety database (approximately 20,000 terms). It 
will form the basis for the mapping of all other findings extracted from the preclinical study 
reports of the different EFPIA partners as described in section 3.3 above. 
  Clinical Chemistry and Toxicology Ontology: This ontology will be based on the terminology 
described recently in the CDISC Standard for Exchange of Nonclinical Data (SEND) 
documentation [36]. This is a relatively simple ontology compared to the other ontologies as 
there are only about 270 terms in the Novartis database, all of them being relatively unique (i.e., 
not many synonyms), hence it will be straightforward to map the terms of all companies to this 
ontology. An advantage of using the SEND terminology consists in the optional automatic 
mapping of preclinical to clinical data. 
  Cell and Tissue Type Ontology: Novartis is also working on a cell and tissue type ontology to 
complement the anatomy ontology that is intended to be shared within the eTOX consortium. 
The rationale behind separating this ontology from the main anatomy ontology is similar to that 
for separating findings from organs, namely that the same cell types occur in many different 
tissues. For example, epithelial cells exist everywhere in the body. Creating a ‘child’ in the 
anatomy ontology with epithelial cells will link many different terms throughout the body – 
skin epithelium, lung epithelium, vascular epithelium, etc. Managing those links would be 
almost impossible. Simple keyword searches/text mapping searches in the cell type ontology 
will automatically provide the links and, since this ontology is rather small, it should not result 
in a loss of performance. As starting point for developing this ontology, Novartis has taken the Int. J. Mol. Sci. 2012, 13  
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ontology maintained by the Jackson Laboratories, which is available from the OBO   
Foundry [37]. 
  Macroscopic and In-Life (“Clinical Findings”) Ontology: This is another ontology that needs 
to be built  from the beginning which will allow the standardization of macroscopic 
observational findings, e.g., skin lesions or hair loss observed during preclinical studies. It is a 
relatively simple ontology, as here too there are only a few hundred, relatively unique, related 
terms in the Novartis database, making easier the mapping of the terms of all companies to this 
ontology. Whether the terms used here may also be mapped to the MedDRA terminology [38] 
is also under investigation. 
  Species and Strain Ontology: This is a simple ontology that describes different characteristics 
of the animals used in preclinical safety studies. While it will be based on the complete 
taxonomy ontology [39], it will consist of simpler associations, such as the term “rodents,” as 
the parent of different rat and mouse strains, as well as hamster, gerbil etc., to allow for simple 
grouping of species. 
  Study Design Vocabularies: They will describe the basic study design parameters, such as time, 
dosage, route etc., and will consist of preferred terms and synonyms, but will not be 
hierarchical.  
3.6. Development of in Silico Models for Prediction of Toxicity & Off Target Pharmacology 
As described above, currently available in silico models cover only a small proportion of the 
toxicological endpoints relevant for drug discovery and development in pharmaceutical companies as 
there are huge differences in the prerequisites for their successful development. Basically, difficulties 
in model development comprise (i) the lack of suitable data for model training and (ii) the complexity 
of the physiological phenomena involved in the in vivo endpoints. 
Regarding difficulty (i), the training of predictive models typically requires the availability of a 
large amount of high quality data, and a substantial series of compounds for which the value of the 
endpoint has been accurately determined. Ideally, the compounds included in these series should be 
designed to cover a significant part of the druggable chemical space and the determinations should be 
made using standardized, reliable experimental methodologies yielding comparable results. In practice, 
the data available from public sources is far from ideal in practically all these aspects and typically, the 
series are small and contain highly similar compounds, often representing congeneric series. The 
aggregation of these series only permits the creation of non-homogeneous datasets in which the 
experimental results have been obtained with highly diverse experimental procedures, thus being non-
comparable and not amenable to statistical analysis. For instance, the data generated using simple 
procedures (e.g., in vitro hERG inhibition) can be used for modeling, since the results (e.g., IC50 > Ki) 
are standardized and comparable between compounds. Nevertheless, data extracted from toxicological 
reports cannot be compared, for several reasons. First and foremost, the doses are adjusted for each 
compound in order to obtain visible toxic results; this is done using non-homogeneous criteria (e.g. 
multiples of expected therapeutic doses, or doses around the value for which toxic effects have been 
observed in preliminary assays). Moreover, the reports tend to suffer from a “positive bias” in the 
sense that they particularly record “positive” findings, i.e., deviations from normal values. Likewise, Int. J. Mol. Sci. 2012, 13  
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animals from control groups are not devoid of abnormalities, therefore constituting a heterogeneous 
background of “normal values”.  
The difficulty (ii) is related to the complexity of the phenomena that the in silico models are 
intended to predict. In some cases, the toxicological outcome depends on relatively simple properties 
of the drug candidate. A good example of this is drug-induced phospholipidosis (PL). Even if the 
mechanism involved in PL is unclear, most of the drugs producing phospholipidosis are cationic 
amphiphilic drugs (CADs) [40,41]. Therefore, any method able to recognize the presence of a positive 
charge and a lipophilic moiety in the drug is able to produce reasonably good predictions and, not 
surprisingly, these models are in the catalogue of models applied in the pharmaceutical industry with 
good results. However, since not all CADs induce phospholipidosis and some drug inducing PL are 
not CADs [42,43], even in this case improvements can still be made. Furthermore, there are many 
other toxicological outcomes, such as hepatotoxicity, that depend on numerous diverse known 
biological mechanisms [44–49] and probably many more unknown ones. Clearly, no single in silico 
approach can be expected to produce a general description of a mechanistically heterogeneous 
endpoint comprising various phenotypes, pointing to the need for a more comprehensive approach. 
The strategies implemented in eTOX for overcoming the first category of difficulty are intrinsic to 
the project design. The pharmaceutical industry has generated a large amount of data during the 
process of drug development, most of which has never been compiled in aggregated electronic formats 
or exploited in any way. Therefore, the data extracted during the project will be collected and compiled 
in a general database, in formats allowing its use for building in silico predictive models. With respect 
to the second category of difficulty, the consortium will use standard methodologies for simple 
endpoints. For complex endpoints, the strategy will be directed to the identification of the simpler (key) 
mechanisms involved and the derivation of predictive models addressing them specifically. These 
predictions will then be integrated, taking advantage of our knowledge about the physiological 
mechanisms involved, for yielding a prediction of the main, observable toxicological outcome. That 
this theoretical approach will have difficulties for its practical application is acknowledged, however, 
some proof of concept applications have already been investigated [8]. In the study undertaken by 
Obiol et al., simulated electrocardiograms were obtained and direct estimations of the induced QT 
elongation produced by the administration of a compound by integrating in silico blocking predictions 
for two separate ion channels (hERG and KCNQ1) using electrophysiological models that represent 
the effect of the drug at cell and tissue levels. This kind of approach, much more representative of the 
complex chain of events leading to cardiotoxicity, produced better prediction for some test compounds 
than in vitro methods based on hERG inhibition only. 
In essence, the implementation of the eTOX modeling strategy in practice will require the 
development of a large collection of single models, each one producing predictions for a relevant 
toxicological endpoint (for the simplest cases) or a single mechanism involved in a complex 
toxicological effect, together with an evaluation of pharmacological aspects with diverse validated 
computational approaches to predict the affinity profile of small molecules against those proteins with 
a somehow intrinsic role in toxicity events. Special attention to well-known target and off-target 
behavior will help anticipate those drug side effects caused by exaggerated pharmacology and extend 
reasoning criteria to complete the toxicological risk assessment for each molecule queried in   
eTOXsys [50]. The pharmacological analysis will be focused on the set of cytochromes P450, Int. J. Mol. Sci. 2012, 13  
 
3835
transporters and others targets like nuclear receptors, G protein-coupled receptors, phase II enzymes, 
kinases, proteases, etc. provided by different EFPIA partners as relevant proteins in those toxicological 
events that the eTOX project aims to predict. 
3.7. The Integrated Prediction System: eTOXsys 
As stated in the introduction, one of the main outcomes of the project will be an in silico prediction 
system, the so-called eTOXsys. The eTOXsys can be described as a software tool able to provide 
useful toxicological risk and hazard assessment, starting from a simple input that, typically, is limited 
to the 2D structure of a compound. For the prediction of complex in vivo endpoints, which require the 
calculation of several variables from the structural information (e.g. log D, volume of distribution, 
absorption, etc.), it is intended to provide the possibility to alternatively input these experimental data, 
if available, to reduce uncertainty in the prediction. 
The core of the eTOXsys will be a data mining tool, which will interface the database to deliver 
nearest neighbors of the compound to be predicted in terms of chemical structure, but also   
pharmaco-toxicological similarities. In addition, the data mining interface will provide the data set for 
subsequent model building or evaluation. The tool will contain a task record facility (audit trail). 
Technical validation aspects laid down in OECD guideline (95)115 will be considered.  
The current strategy for the development of predictive tools for organ toxicity from the collected 
data of systemic toxicity studies is to assign the individual parameters measured in an in vivo study to 
specific organs (e.g. transaminases, bilirubin to liver, troponin to heart, etc.). Subsequently, the 
observed changes of these parameters will be attributed to levels of severity based on the conventional 
toxicological knowledge and the assessment provided in the original reports. Based on the analyses, 
data sets will be created from which models for each organ can be constructed. If several models exist 
for individual organs, the intention is to combine these with a reasoning engine, again built on classical 
toxicological experience (e.g., if, for “compound x,” “transaminase” is “weakly elevated” and “no 
histopathological findings in liver” then, “low probability for liver toxicity”).   
 
3.7.1. The Conceptual Design of the eTOXsys 
From a technical point of view, eTOXsys will be a unified software platform integrating the various 
tools, databases and results achieved during the course of the project. This integrated software system 
will provide access to all existing and developed predictive models and databases through a uniform 
user interface to support the hazard identification and risk assessment of drug candidates. 
To define the requirements of the predictive system, the eTOX partners FIMIM and Molecular 
Networks carried out surveys to assess both EFPIA partners’ expectations in such a system, as well as 
the expertise, know-how and skills of the academic organizations and SMEs which will mainly be 
involved in the development of the predictive models and software. 
On the EFPIA side, the results of the survey indicated that the software will be used in the drug 
discovery & development stages to save money, time and animals and to design new compounds, 
prioritize compounds and to decide testing strategies. The system may also be applied for the 
assessment of impurities or synthesis intermediates. A user group consisting of toxicologists, Int. J. Mol. Sci. 2012, 13  
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medicinal and computational chemists, pharmacologists and biologists is envisaged. Real use cases 
will be compiled by means of another questionnaire that will be presented to the consortium members 
alongside a User Centered Design methodology. 
As the modelers are using a diversity of programming languages, software tools and techniques, the 
results of the surveys suggested the implementation of a distributed and decoupled system architecture 
based on the web services paradigm. The eTOXsys platform is managed by a lightweight server 
(eTOXsys server) centralizing the communication between the end user and the components of the 
system: the prediction models, the eTOX database, other external databases and the reasoning module 
consolidating the data and the predictions. At present, every module is being hosted by the partner in 
charge of its development, but in the final version, the whole system will be installed within the 
company facilities, ensuring that no sensitive information is transferred via the internet. Furthermore, 
authentication is handled by a web service linking existing company user management systems (such 
as LDAP or Active Directory) to the eTOXsys. All web service modules will communicate through a 
well-defined REST Application Programming Interface (API).  
The conceptual design and potential workflow of the eTOX system are outlined in Figure 5. On the 
client (user) side, the interface to the eTOX system is run in a standard web browser. In general, the 
eTOX system is chemical structure-centered and workflows are oriented on operations related to 
chemical structures and their features and properties, but in a fully flexible and user-defined manner. 
For an investigation, the user can submit queries to the system by either entering a 2D structure sketch 
through a graphical molecule editor or by uploading a structure file (e.g., a single or multi-record 
SDFile). The eTOX database (eTOX DB) is plugged into the system by a web service hosted by Lhasa 
Limited that provides unified access to the stored data. For structure queries, the eTOX database can 
be searched in full structure or substructure mode. Furthermore, the system supports text-based 
searches, such as for registry numbers, names or properties of chemicals. In the final version of the 
system, the user will optionally also be able to enter measured data with the query, e.g., from in vitro 
experiments, which are then used in the prediction services as these values are likely to be more valid 
than calculated values. The results from a database query are presented in chemical table and 
compound views which can be sorted, further refined and adjusted to the needs of the user. Missing 
data points and information that is required for analyzing the risk potential of a chemical can be 
predicted by various in silico models for toxicity endpoints and ADME parameters (see section 3.7.2 
"The predictive models battery") which are registered and available in the system as web services. In 
addition, the concept of DMPK-related toxicity is taken into account. Potential phase I and II 
metabolites of the query (parent) compound(s) can be either retrieved from the eTOX database or, if 
no or limited information is available, generated by a metabolite prediction web service. The retrieved 
and predicted metabolites can be re-submitted to the above-described database query and toxicity 
prediction processes. After all necessary and available information has been gathered, a reasoning 
engine will optionally consolidate the data and predictions obtained from the various services in order 
to support the user to assess the potential hazard or safety of the queried compound(s). Compound 
datasets and associated information that have been compiled from search results can be stored, 
managed and shared among user groups or exported in spreadsheet-compatible formats (e.g., tab or 
comma-separated value files) for further analysis from which reports can be generated. Int. J. Mol. Sci. 2012, 13  
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In summary, the final eTOXsys will be a Decision Support System collecting the individual 
predictions of each separate service, evaluating the overall outcome and providing guidance to the user 
on the basis of the evaluation and consolidation of the data available. At each step, the system will be 
sufficiently transparent to enable the user to drill down into the result to determine the underlying data 
and information and methodologies that led to the predictions. However, confidential data of the 
individual partners will not be disclosed at any stage. For the eTOX database and database web service 
in particular, encryption, strict authentication and access rights policies and secure communication 
protocols will be employed to secure proprietary information and data. 
Figure 5. Conceptual design and a potential workflow of the eTOX system (eTOXsys, 
prediction system established by eTOX). 
 
The eTOX system will support the inclusion of different types of predictive models including 
QSAR algorithms, machine learning techniques and knowledge-base expert systems. A mixed license 
environment will be operated so that proprietary and open source web services can be incorporated for 
greatest extensibility. However, web service providers will be asked to use open source components 
whenever possible. 
The models available as web services in the eTOX system will mostly incorporate their own 
algorithms and descriptor generators. However, to avoid unnecessary duplication of computational 
resources, the integrated system will also support the inclusion of common algorithms and descriptor 
generators that are frequently used. 
The intention is for the models to initially be hosted by each of the model developers and as the 
project progresses to move towards the models being installed in-house on the user organization’s own 
server to allow training or validation of models using in-house data. Int. J. Mol. Sci. 2012, 13  
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Dynamic registries of available prediction web services and database services are foreseen. These 
registries will continuously check the availability of known services and dynamically register newly 
deployed services. If a service is not available during the status check, the service provider will be 
notified about the problem. 
As there are likely to be differences in the acceptance of particular models by different users, for 
example on the basis of internal validation exercises, the user will be able to select the models and 
services to be applied in the queries. The default option will be to run all available and applicable 
models, but the user will also be able to choose to run just one (e.g., after a model has been upgraded) 
or only a sub-selection. If no predictions are available, the system will report this. 
The advantages of the eTOXsys result from two major achievements initiated and implemented by 
the eTOX consortium. First, the flexibility of a state-of-the-art web service-based system allows for a 
seamless integration of various distributed modules and services provided, maintained and further 
developed by different expert groups as well as the inclusion of company-adopted authentication 
mechanisms or data access policies. Secondly, the level of quality and originality of the data and 
information provided by the EFPIA partners enables the computational chemists and toxicologists to 
better capture real-life challenges with their models and to transfer information into valuable 
knowledge. 
 
3.7.2. The Predictive Models Battery 
In the previous sections, the eTOX strategy for the development of in silico prediction methods was 
advanced. The implementation in practice will require the development of a large collection of single 
models, each one producing predictions for a relevant toxicological endpoint (for the simplest cases) or 
a single mechanism involved in the toxicological effect. 
In eTOXsys, the in silico methods used for deriving the predictions fall into three main categories: 
(i) pure-chemistry based methods (ii) QSAR models (iii) structure-based or mechanistic methods. 
Pure-chemistry approaches are based on the recognition of molecular fragments or substructures linked 
to the presence of toxicity (toxicophores). Methods based on the calculation of molecular properties 
(e.g., pKa) fall also in this category. In QSAR methods, a training set of compounds of known 
biological properties is used to train a statistical model, describing the relationship between such 
biological properties and the compound structure. In the last approach, the structure-based or 
mechanistic methods, the toxicity of the compounds is predicted based on simulations involving the 
structure of a biomolecule important for the events leading to the toxic effect (e.g., blocking a bile 
transporter or the potassium hERG ion channel). The choice of the methods depends mainly of the 
availability of a priori knowledge, the relationship between the presence of fragments and toxicity in 
pure-chemistry methods, a good training series in QSAR methods, and the identity and three-
dimensional structure of a highly relevant biomolecule, in structure-based methods. Clearly, this 
knowledge is not readily available for all relevant toxicological endpoints, and a large part of the effort 
of developing eTOXsys will be devoted to the compilation and harmonization of knowledge from 
public and private sources, as described in previous sections. 
In a subsequent step, the results produced by the different models will be integrated to enable higher 
order predictions. The methods used for this integration are diverse. In cases in which several models Int. J. Mol. Sci. 2012, 13  
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produce predictions for the same endpoint, the integration only aims to combine the predictions by 
obtaining a more accurate consensus result. In other cases, the results of DMPK prediction will 
determine the expected exposure of the targets to the drug. Even further, metabolic models can predict 
the presence of a given metabolite for which a full panel of predictions will be carried out in turn. 
Probably, more sophisticated integration approaches will be required for the complex endpoints. In 
these cases, the predictions describing individual mechanisms will be integrated using mathematical or 
logical models reflecting a priori knowledge about the physiology of the process. As indicated above, 
in spite of some success of the previously mentioned proof of concept application [8], this latter case 
suggests a high degree of difficulty and it is unlikely that the present project will generate this type of 
sophisticated approach for the prediction of all the relevant in vivo toxicological outcomes. 
 
3.7.3. The Prediction Models Web Services 
The concept of the prediction engine as a collection of independent models fits well with the 
software architecture described above. Every model is implemented as an independent web service, 
receiving a well-defined input (typically, the structure of the candidate compound) and yielding an 
output consisting of a prediction value, together with some additional information necessary for the 
correct integration of the results (e.g., some scoring of the prediction quality). Moreover, this 
architecture allows the distributed development of every prediction model, which can be performed in 
parallel by diverse partners and can be easily extended in the future by the pharmaceutical companies 
and/or other third parties. 
The integration of every single prediction, as depicted in the eTOXsys conceptual design, is carried 
out by a separate module, also working as a web service, producing an output that will be processed in 
order to present the results in understandable format. This latter step is also very important, since the 
end users need to obtain a clear picture of the prediction results, translated in terms of toxicity risks. 
Different approaches have been published for this task in the field of toxicology [51–54]. In eTOXsys, 
it is planned to carry out systematic tests to choose the most suitable method or combination of 
methods. An important factor in the choice of integrative tools is the ability of the method to provide 
reliability indices and the ability to mine for detailed information on the background of any particular 
prediction (e.g., the method used, the details of the computation, structure of the nearest compound in 
the training series, etc.). 
4. Current Achievements and Future Deliverables 
The achievements obtained so far in eTOX can be classified in three domains: data gathering and 
collection, database building, and development of the predictive system. 
The data gathering and collection, as a result of the aforementioned need to retrieve and release 
proprietary data, is progressing at a low pace, slower than envisaged. However, having now completed 
the pilot study to assess data extraction by potential subcontractors, the project is now in position to 
move forward rapidly. Also in this domain, the protection of data considered sensitive by their owners 
and the potential usefulness of diverse state-of-the-art structure masking methods have been tested, 
analyzing their strengths, weaknesses and potential threats. From this study, it was concluded in Int. J. Mol. Sci. 2012, 13  
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agreement with other authors that no structure masking method on its own would provide the level of 
protection required. However, the particular set-up of the project and the participation of a trusted 
partner will allow the implementation of original structure protection protocols suitable for the 
purposes of the project. 
Regarding the database building, a first version of the eTOX database using the schema and 
database infrastructure (Vitic Nexus) described in previous sections is fully operative, and is being fed 
with real data extracted from the legacy reports. Also, a significant amount of publically available 
toxicological data has been collected in the ChOX database, which at present contains information for 
more than 153,520 single compounds. Plans to merge the contents providing a single access point to 
all the data collected in the project are already in progress. This integrated database will also be 
accessible as a web service, in accordance to the designed system architecture; a first version of this is 
undergoing testing. 
With respect to the eTOXsys platform, the overall architecture and the communication protocols 
have been defined (see section 3.7). Several of the modules configuring the system have been 
developed and are provided as web services independently at the sites of the respective developing 
partners. A pilot study, focused on the prediction of a simple in vivo endpoint (phospholipidosis), was 
run among the partners with positive results. A first proof of concept (POC) version of the eTOXsys 
has been implemented and presented to the consortium to demonstrate the interplay of user interface 
and predictive models provided as web services. Figure 6 shows a screenshot of this POC version. A 
first prototype of the eTOXsys for internal review by the consortium is planned for delivery by end of 
February 2012. 
 
Figure 6. Screenshots of the current version of the eTOX system (eTOXsys). 
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Additionally, a great deal of effort has been put into building the project intranet, which constitutes 
a portal to numerous and valuable resources, including an updated index of toxicological bibliography, 
links to diverse toxicology databases and public datasets. The portal also hosts collaborative tools 
(wiki, discussion forums, etc.) and a central repository of management documents. 
5. Discussion and Outlook 
For the first time in pharmaco-toxicological research, a wealth of unused or poorly used, highly 
relevant preclinical drug safety data will be combined to improve the quality of drug candidates and 
the processes for their development leading to better safety, a faster process to the benefit of patients 
and a reduction of animal use.  
The database arising from the project is likely to be the largest repository for high quality repeat 
dose toxicity data currently existing. The number of entries in such a database is obviously important 
for accurate drug side effects prediction. However, the quality and the chemical space coverage is 
equally, if not more important. The pharmaceutical toxicity data that will be used have been produced 
with compounds that have become drugs and many more chemicals that have failed to reach the 
market. These compounds may have been dropped from further development for many reasons, 
including safety issues. No matter what, these molecules cover a large chemical space thought to be 
the best fit for druggable structures. Hence, the nature of the toxicity data collected for the eTOX 
database represent the best possible space coverage for toxicity prediction of future potential drugs. 
The relevance of these data is reinforced by the high quality required for GLP studies. Furthermore, 
existing relevant databases for eTOX, as well as collated, published data, complements in many ways 
the EFPIA data by increasing the chemical space and the parameters of the eTOX database. These two 
distinct aspects, relevance of the covered chemical space and data quality, bring together the essential 
background for accurate in silico toxicity prediction. 
The computerized software that is being developed in the eTOX project (eTOXsys) will take 
advantage of these data. Meanwhile, many aspects have to be taken into account for accurate 
predictions of toxicity. Toxicological events are very complex phenomena which depend on the 
chemical structure of the drug, the biological targets, their location within the cells, the perturbation of 
the biological pathways that include the targets, the function of these targets in different organs, the 
physiology of the whole organism, the pharmacokinetic characteristics of the compound, the potential 
toxic metabolites, the route of administration, the dose, the dose regimen, the duration of the treatment 
and the recipient species, all of which play a role which, at present, is far from being well understood 
and characterized. Therefore, the in silico predictions will be based on both relevant knowledge and 
observations of the overall outcome to animal treatment as described in the toxicity legacy reports. The 
synergy between the expert knowledge from the pharmaceutical toxicologists and professional input 
from academic and SME modelers will be critical to the success of the project. 
At present, the pharmaceutical industry partners are gathering their proprietary data to be used in 
eTOXsys and, as mentioned before, thorough security measures have been taken to protect intellectual 
property rights and secrecy of sensitive data, while still allowing their usage in the training of the 
predictive system. This specific feature establishes a major difference between eTOX and any open 
platform like the OpenTox project [18]. Once authorized to be sent out to the consortium, toxicity Int. J. Mol. Sci. 2012, 13  
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report data will be accurately extracted, capturing heterogeneous data, acquiring data in a coherent 
manner from highly different formats from various companies, utilizing the standards and 
harmonization of procedures already developed. Likewise, to be able to exploit the extracted data, a 
standardization of terminology is necessary and hence much time and resource has been spent in the 
development of an accurate ontology for mapping all used terms, from the straightforward description 
of the study design to complex histopathology findings. Academic partners are also gathering and 
capturing data and are experiencing difficulties inherent to published data where a quality judgment 
has to be made. Re-using existing databases for the sake of eTOX also requires careful manipulation of 
structure and format to prevent compatibility issues.  
Overall, the eTOX database is being populated with preclinical toxicology data, mainly from 
rodents, as well as conventional non-rodent species: dog and more occasionally, monkey. The initial 
studies collected are classical GLP repeat dose studies and drug metabolism and pharmacokinetics 
studies in the same species. However, the in vitro pharmacology data are mostly from human receptors 
and targets. There will be necessary additional work to allow translation from pre-clinical to clinical 
prediction. Furthermore, more complex studies such as reprotoxicity and carcinogenicity reports could, 
and should, also be included in eTOX. For all these reasons, together with the fact that pharmaceutical 
companies are constantly generating new toxicity reports, the possibility of extending the scope and 
duration of this project is being envisaged. In any case, the eTOX database will not be a frozen system 
at the end of the consortium. Maintenance and improvement of prediction systems, as well as the 
permanent incorporation of new data, will have to be accommodated. 
Within three years from now, the eTOX project and with it, the database and the exploitation 
systems (both toxicity prediction and data mining), will be close to its scheduled end. At this point it 
will be clear how many of the identified hurdles will have been overcome and whether or not this 
consortium will have delivered its promises. However, one battle is already won: pulling together 
highly competent forces to move forward drug discovery and development to its best possible outcome 
is already in place and moving forward. Indeed, more than three years ago now, when this project was 
being conceived, bringing together competing pharmaceutical companies, with academic partners 
usually more focused on pure sciences than in concrete applications, together with SMEs whose 
normal function is as providers rather than partners, under a European institution (IMI), was perhaps 
the biggest challenge of all. This challenge has been taken up by the eTOX consortium with one 
common goal: improving medicine quality. 
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